Nkarta (NKTX) Projected to Announce Quarterly Earnings on Tuesday

Nkarta (NASDAQ:NKTX) is expected to be releasing its Q3 2026 resultson Tuesday, November 10th. Analysts expect Nkarta to announce earnings of ($0.40) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18). On average, analysts expect Nkarta to post ($1.60) EPS for the current fiscal year and ($1.46) EPS for the next fiscal year.

Nkarta Price Performance

Shares of NKTX stock traded up $0.04 during trading hours on Tuesday, reaching $1.56. 231,659 shares of the company were exchanged, compared to its average volume of 759,912. Nkarta has a fifty-two week low of $1.48 and a fifty-two week high of $3.72. The stock’s fifty day moving average is $2.42 and its two-hundred day moving average is $2.52. The company has a market cap of $112.09 million, a price-to-earnings ratio of -1.00 and a beta of 0.93.

Analysts Set New Price Targets

Several research analysts have issued reports on NKTX shares. Stifel Nicolaus reduced their price objective on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. HC Wainwright started coverage on Nkarta in a research note on Monday. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, September 21st. Finally, Wall Street Zen downgraded Nkarta from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.20.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.